GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

Phase 3

Withdrawn

Conditions: Infections, Respiratory Tract

Interventions: Drug: Paracetamol, phenylephrine HCl, and vitamin C

First Posted Date: 2016-02-09

Last Posted Date: 2018-03-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02678234

A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

Phase 2

Completed

Conditions: Shigella Sonnei Infection

Interventions: Biological: GVGH S. sonnei (1790GAHB) vaccine 25 μg
Biological: Menveo
Biological: GVGH S. sonnei (1790GAHB) vaccine 100 μg
Biological: Boostrix

First Posted Date: 2016-02-08

Last Posted Date: 2019-02-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 74

Registration Number: NCT02676895

Locations: 🇰🇪
GSK Investigational Site, Kilifi, Kenya

A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis

Phase 1

Withdrawn

Conditions: Autoimmune Diseases

Interventions: Drug: Placebo
Drug: GSK3050002

First Posted Date: 2016-02-02

Last Posted Date: 2018-08-31

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02671188

Locations: 🇬🇧
GSK Investigational Site, Oxford, United Kingdom

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BAT/FF
Drug: BAT
Drug: FF
Drug: FF (MgSt)
Drug: FF/Vilanterol

First Posted Date: 2016-01-28

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT02666287

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.

Completed

Conditions: Influenza, Human

Interventions: Other: Data collection

First Posted Date: 2016-01-26

Last Posted Date: 2024-04-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1388

Registration Number: NCT02663102

Locations: 🇰🇷
GSK Investigational Site, Yangju-si, Gyeonggi-do, Korea, Republic of

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Albiglutide Liquid Auto-injector
Drug: Albiglutide Lyophilized DCC Pen Injector
Drug: Placebo Liquid Auto-injector
Drug: Placebo Lyophilized DCC Pen injector

First Posted Date: 2016-01-21

Last Posted Date: 2016-11-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 59

Registration Number: NCT02660736

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Asthma and Rhinitis
Respiratory Disorders

Interventions: Drug: Test Montelukast
Drug: Reference Montelukast

First Posted Date: 2016-01-18

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT02658422

Locations: 🇮🇳
GSK Investigational Site, Telangana, India

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

Phase 1

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Tafenoquine 150 mg
Drug: Matched placebo 150mg

First Posted Date: 2016-01-18

Last Posted Date: 2018-03-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 486

Registration Number: NCT02658435

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Mepolizumab 100mg SC
Drug: Albuterol/salbutamol MDIs
Drug: Omalizumab

First Posted Date: 2016-01-13

Last Posted Date: 2019-08-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 145

Registration Number: NCT02654145

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

Not Applicable

Completed

Conditions: Dentin Sensitivity

Interventions: Other: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)
Other: Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)
Other: Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )

First Posted Date: 2016-01-11

Last Posted Date: 2018-08-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 221

Registration Number: NCT02651467

Locations: 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States

Home Terms & Conditions Privacy Policy